title: Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.
abstract: Fluorine-18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) was used to image 38 patients with known or suspected malignant processes involving the abdomen or pelvis (including primary [n = 2] and secondary [n = 19] liver tumors, recurrent colon carcinoma [n = 1], lymphoma [n = 15], and cavernous hemangioma [n = 1]). PET results were compared with those from concurrent computed tomographic (CT) studies. Conspicuity of metastatic liver lesions on PET images often exceeded that of lesions on CT scans. Two well-differentiated primary liver tumors failed to show increased FDG uptake. Thirteen of the 15 patients with lymphoma had active disease, as determined with CT or clinical findings; 12 of 13 had increased FDG uptake on PET images. The false-negative result occurred in a patient with a low-grade lymphoma. The recurrent colorectal lesion was well demonstrated by PET, but further study is needed to determine whether it can be used to distinguish recurrent disease from radiation-induced changes. PET may be useful in determining the response to oncologic therapy, but PET does not reliably allow exclusion of low-grade lymphoma or well-differentiated hepatic lesions. Clinical correlation is always required in evaluating the significance of PET findings, as inflammatory conditions can also result in increased FDG uptake.
authors.affiliation: Department of Radiology, Massachusetts General Hospital, Boston 02114.
authors.forename: M A
authors.initials: MA
authors.lastname: Goldberg
authors.forename: M J
authors.initials: MJ
authors.lastname: Lee
authors.forename: A J
authors.initials: AJ
authors.lastname: Fischman
authors.forename: P R
authors.initials: PR
authors.lastname: Mueller
authors.forename: N M
authors.initials: NM
authors.lastname: Alpert
authors.forename: J H
authors.initials: JH
authors.lastname: Thrall
mesh_terms: D000008:Abdominal Neoplasms / Q000000981:diagnostic imaging*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging*; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D019788:Fluorodeoxyglucose F18; D006392:Hemangioma, Cavernous / Q000000981:diagnostic imaging; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D010386:Pelvic Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
chemical_list: D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose